Status:
COMPLETED
Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Pancreas Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Perioperative immunologic signatures can predict the risk of postoperative complications. The results will be puplished as two smanuscripts. The manuscript will focus on preoperative immunologisk dat...
Detailed Description
OBJECTIVE Establish evidence for perioperative immunologic risk stratification of patient's risk for clinically postoperative inflammatory complications as a basis for future mechanism-based intervent...
Eligibility Criteria
Inclusion
- Scheduled for PD on the suspicion of pancreatic cancer
- Patients able to follow standardised surgical procedure including TIVA anaesthesia with epidural
Exclusion
- Bilirubin \>100 µmol/ltr
- Patients receiving immunomodulating treatment 1 month properatively and/or autoimmune diseases and patients non-cenacerous cystic lessions
- Patients scheduled for simultaneous procedures on major arterial blood vessels, and/or adjacent organs (spleen, liver)
- Inoperable patients, for instance, due to carcinosis, circulatory/ventilatory instability hindering procedure completion and/or concomitant surgery on major arterial blood vessels, spleen, or liver, are excluded post-inclusion and will not be part of the primary analysis
- ongoing treatment with glucocortocoid, anti-tnf-alpha etc.
- patients diagnosed with rheumatological diseases, IBD or chronic infection (eg. HIV)
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 7 2024
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04774198
Start Date
February 1 2021
End Date
January 7 2024
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100